Vimarsana
Biggest News Aggregation in the World

Jba Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jba Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jba Inc Today - Breaking & Trending Today

ABioVaxys Technology Corp: BioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal Study - Vimarsana News

ABioVaxys Technology Corp: BioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal Study

VANCOUVER, BC, Dec. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that possibly based on the selected study

BioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal Study - Vimarsana News

BioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal Study

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that possibly based on the selected...

BioVaxys Co-Founder, President - GuruFocus.com - Vimarsana News

BioVaxys Co-Founder, President - GuruFocus.com

GuruFocus Article or News written by PRNewswire and the topic is about:

BioVaxys Technology Corp.: BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine - Vimarsana News

BioVaxys Technology Corp.: BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free

BioVaxys Technology Corp.: BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 - Vimarsana News

BioVaxys Technology Corp.: BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing